Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.34 | N/A | +17.87% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.34 | N/A | +17.87% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current market conditions. They reiterated their commitment to long-term growth despite recent challenges.
Management acknowledged ongoing challenges in the market.
They emphasized a focus on long-term strategies despite short-term setbacks.
Nektar Therapeutics reported a wider-than-expected loss per share, which contributed to a 3.25% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's short-term outlook. Management's cautious tone suggests they are navigating a challenging environment, which could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BARRICK MNG CORP
May 4, 2009